Urothelial carcinoma: S100P and GATA3

 Reference 1

Polyclonal anti-S100P, S0084

% positive (number of cases studied), nuclear with or without cytoplasmic

monoclonal S100P

% positive (number of cases studied), nuclear with or without cytoplasmic

GATA3

% positive (number of cases studied)

Renal urothelial

94% of 17

80% of 15

67% of 15

Bladder urothelial, high grade

81% of 215

71% of 219

57% of 226

Bladder urothelial, low grade

100% of 80

96% of 81

95% of 82

Bladder urothelial, all

86% of 295(strongly positive in 78% of cases)

78% of 300(strongly positive in 62% of cases)

67% of 308

Bladder, squamous cell

0 of 7

0 of 7

0 of 7

Stomach

58% of 19

62% of 21

0 of 15

Oesophageal adenocarcinoma

4 of 4

3 of 5

0 of 4

Oesophageal squamous

0 of 7

0 of 8

0 of 8

Pancreatic

4 of 6

3 of 10

0 of 6

Colorectal

61% of 72

20% of 80

0 of 71

Hepatocellular

36% of 11

14% of 14

0 of 13

Lung

27% of 41

10% of 48

0 of 45

Ovary

15% of 40

7% of 41

0 of 39

Prostate

3% of 260

2% of 256

0 of 257

Adrenal

0 of 3

0 of 3

0 of 3

Breast ductal

1 of 4

0 of 4

4 of 4

Cervical adenocarcinoma

1 of 4

0 of 5

0 of 4

Cervical squamous

2 of 4

0 of 6

0 of 6

Endometrial

7% of 30

0 of 31

0 of 27

Gallbladder

0 of 1

0 of 1

0 of 1

Melanoma

0 of 13

0 of 16

0 of 12

Renal clear cell

1% of 125

0 of 125

0 of 111

Renal papillary

0 of 9

0 of 9

0 of 9

Renal chromophobe

0 of 12

0 of 12

0 of 11

Renal sarcomatoid

0 of 2

0 of 2

0 of 2

Seminoma

0 of 10

0 of 10

0 of 6

Squamous NOS

19% of 16

0 of 20

0 of 23

Thyroid

0 of 14

0 of 17

0 of 18

p63

CK5/6

urothelial carcinoma

87% of 292 cases(80% of the total were strongly positive)

54% of 293 cases(22% of the total were strongly positive)

renal cell carcinoma

0 of 117 cases

7 of 131 cases

prostatic carcinoma

1 of 251 cases

11 of 254